BCG vaccine
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
1
Recruiting
0
Completed
2
Sites
3
Countries
2
Endpoints
33
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 33 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 11 of 33 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
5
4
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| BCG-ADDoes BCG Vaccination Reduce Biomarkers of Alzheimer's Disease? | BCG vaccine Alzheimer’s disease | MoCA ≥26 | Early Ph 1 | By invitation | 1 | Dec 2025 | - | |
| NCT05004688A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD | BCG vaccine Alzheimer’s disease, MCI / preclinical Alzheimer’s | Alzheimer's disease | Ph 2 | Completed | 1 | Jan 2024 | 1 | results |
| NCT04449926BCG and Plasma Amyloid in Non-Demented Adults | BCG vaccine Alzheimer’s disease | Age 50-80 | Ph 2 | Completed | 1 | Dec 2021 | 7 |
Showing 1-3 of 3 trials